Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020
出版年份 2022 全文链接
标题
Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 5, Pages -
出版商
American Society for Microbiology
发表日期
2022-04-26
DOI
10.1128/aac.00054-22
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
- (2022) Christopher JL Murray et al. LANCET
- Interaction Mode of the Novel Monobactam AIC499 Targeting Penicillin Binding Protein 3 of Gram-Negative Bacteria
- (2021) Stefan Freischem et al. Biomolecules
- Antibiotics in the clinical pipeline in October 2019
- (2020) Mark S. Butler et al. JOURNAL OF ANTIBIOTICS
- Critical analysis of antibacterial agents in clinical development
- (2020) Ursula Theuretzbacher et al. NATURE REVIEWS MICROBIOLOGY
- An Analysis of Antibacterial Drug Development Trends in the US, 1980 – 2019
- (2020) Nidhi Dheman et al. CLINICAL INFECTIOUS DISEASES
- Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
- (2020) Yudibeth Sixto-López et al. Scientific Reports
- In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains
- (2020) Le Phuong Nguyen et al. Antibiotics-Basel
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Improving data sharing to increase the efficiency of antibiotic R&D
- (2020) Wes Kim et al. NATURE REVIEWS DRUG DISCOVERY
- N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay
- (2020) Takeru Furuya et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The Concept of an Ideal Antibiotic: Implications for Drug Design
- (2019) Márió Gajdács MOLECULES
- Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies
- (2019) Laura L. McDowell et al. SLAS Discovery
- Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
- (2019) J. C. Bader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, An Intravenous Potentiator, After Single and Multiple Ascending Doses and When Combined with Beta-Lactam Antibiotics in Healthy Subjects
- (2019) Paul B. Eckburg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potent LpxC Inhibitors with In Vitro Activity Against Multi-Drug Resistant Pseudomonas aeruginosa
- (2019) Kevin M. Krause et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety
- (2019) Frederick Cohen et al. ChemMedChem
- The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
- (2019) Krisztina M. Papp-Wallace EXPERT OPINION ON PHARMACOTHERAPY
- Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
- (2019) Roger Echols et al. CLINICAL INFECTIOUS DISEASES
- The global preclinical antibacterial pipeline
- (2019) Ursula Theuretzbacher et al. NATURE REVIEWS MICROBIOLOGY
- A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa
- (2018) Gloria Andolina et al. ACS Chemical Biology
- Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China
- (2018) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses
- (2018) Achim Wach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Murepavadin, a novel antipseudomonal antibiotic: Pharmacokinetics, tolerability and safety in subjects with mild, moderate, and severe renal function impairment
- (2018) Glenn E. Dale et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model
- (2018) Sean M. Stainton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Murepavadin: a new antibiotic class in the pipeline
- (2018) Ignacio Martin-Loeches et al. Expert Review of Anti-Infective Therapy
- Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
- (2018) Mark A. T. Blaskovich et al. Expert Review of Anti-Infective Therapy
- Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Revitalizing the drug pipeline: AntibioticDB, an open access database to aid antibacterial research and development
- (2018) L J Farrell et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Past and Present Perspectives on β-Lactamases
- (2018) Karen Bush ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
- (2018) Burcu Isler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phenylethylene glycol-derived LpxC inhibitors with diverse Zn2+-binding groups
- (2018) Magdalena Galster et al. TETRAHEDRON
- Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers
- (2018) David Tenero et al. Clinical Pharmacology in Drug Development
- LpxC inhibitors: a patent review (2010-2016)
- (2017) Dmitrii V. Kalinin et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens
- (2017) Sang-Hun Oh et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Heterocyclyl tetracyclines. 2. 7-Methoxy-8-pyrrolidinyltetracyclines: discovery of TP-2758, a potent, orally efficacious antimicrobial against Gram-negative pathogens
- (2017) Cuixiang Sun et al. JOURNAL OF ANTIBIOTICS
- In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model
- (2017) Kentaro Nagaoka et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs
- (2017) Helen W Boucher et al. JOURNAL OF INFECTIOUS DISEASES
- Recent advances and perspectives in the design and development of polymyxins
- (2017) Francesc Rabanal et al. NATURAL PRODUCT REPORTS
- Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects
- (2016) Marion Straubinger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhaled Antibiotics for Gram-Negative Respiratory Infections
- (2016) Eric Wenzler et al. CLINICAL MICROBIOLOGY REVIEWS
- Polymyxins: a new hope in combating Gram-negative superbugs?
- (2016) Tony Velkov et al. Future Medicinal Chemistry
- Synergistic combinations of polymyxins
- (2016) Justin R. Lenhard et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
- (2016) Alejandra Gallardo-Godoy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability
- (2016) Wu-Yan Zhang et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Polymyxin: Alternative Mechanisms of Action and Resistance
- (2016) Michael J. Trimble et al. Cold Spring Harbor Perspectives in Medicine
- Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC
- (2016) Alice L. Erwin Cold Spring Harbor Perspectives in Medicine
- OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’
- (2015) Akihiro Morinaka et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria
- (2015) Kade D. Roberts et al. ACS Infectious Diseases
- Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009
- (2015) Kevin Outterson et al. JOURNAL OF LAW MEDICINE & ETHICS
- Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections
- (2014) Karen O'Dwyer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cell- and biomarker-based assays for predicting nephrotoxicity
- (2014) Johnny X Huang et al. Expert Opinion on Drug Metabolism & Toxicology
- Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model
- (2014) Saito Higuchi et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Structural basis for outer membrane lipopolysaccharide insertion
- (2014) Haohao Dong et al. NATURE
- Structural basis for lipopolysaccharide insertion in the bacterial outer membrane
- (2014) Shuai Qiao et al. NATURE
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Discovery and preclinical development of new antibiotics
- (2014) Diarmaid Hughes et al. UPSALA JOURNAL OF MEDICAL SCIENCES
- Siderophore conjugates
- (2013) Malcolm G. P. Page Annals of the New York Academy of Sciences
- Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems
- (2013) Oren Zusman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers
- (2013) David Tenero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ComparativeIn VitroActivities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms
- (2013) Ellie J. C. Goldstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- PotentIn VitroAntibacterial Activity of DS-8587, a Novel Broad-Spectrum Quinolone, against Acinetobacter baumannii
- (2013) Saito Higuchi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria
- (2013) Vincent Hernandez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli
- (2013) Rodrigo E. Mendes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural studies of β-hairpin peptidomimetic antibiotics that target LptD in Pseudomonas sp.
- (2013) Jasmin Schmidt et al. BIOORGANIC & MEDICINAL CHEMISTRY
- In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens
- (2013) Michael Hornsey et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli
- (2013) B. Hofer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inhibition of Lipopolysaccharide Transport to the Outer Membrane in Pseudomonas aeruginosa by Peptidomimetic Antibiotics
- (2012) Martina Werneburg et al. CHEMBIOCHEM
- UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents
- (2012) J. Zhang et al. CURRENT MEDICINAL CHEMISTRY
- In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii
- (2012) P. G. Higgins et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis
- (2012) L. Lin et al. mBio
- Challenges of Antibacterial Discovery
- (2011) L. L. Silver CLINICAL MICROBIOLOGY REVIEWS
- In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii
- (2011) T. A. Russo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City
- (2011) John Quale et al. Microbial Drug Resistance
- A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane
- (2010) M. Vaara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
- (2010) M. G. P. Page et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa
- (2010) N. Srinivas et al. SCIENCE
- Siderophores as drug delivery agents: application of the “Trojan Horse” strategy
- (2009) Ute Möllmann et al. BIOMETALS
- Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans
- (2008) D. Dalvie et al. DRUG METABOLISM AND DISPOSITION
- Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
- (2008) Rosemarie O’Shea et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now